Akebia Therapeutics Inc. (NASDAQ: AKBA) is 8.87% higher on its value in year-to-date trading and has touched a low of $0.78 and a high of $2.48 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKBA stock was last observed hovering at around $1.37 in the last trading session, with the day’s loss setting it -0.02%.
Currently trading at $1.35, the stock is -7.36% and -1.63% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.44 million and changing -1.46% at the moment leaves the stock -1.12% off its SMA200. AKBA registered 8.87% gain for a year compared to 6-month loss of -26.23%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -9.40% gain in the last 1 month and extending the period to 3 months gives it a 33.66%, and is -6.25% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.78% over the week and 5.93% over the month.
Akebia Therapeutics Inc. (AKBA) has around 167 employees, a market worth around $283.89M and $174.50M in sales. Profit margin for the company is -23.18%. Distance from 52-week low is 73.05% and -45.56% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.51%).
The EPS is expected to grow by 13.10% this year
130.0 institutions hold shares in Akebia Therapeutics Inc. (AKBA), with institutional investors hold 27.60% of the company’s shares. The shares outstanding are 210.29M, and float is at 199.72M with Short Float at 9.55%. Institutions hold 27.00% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 11.64 million shares valued at $11.87 million. The investor’s holdings represent 5.6786 of the AKBA Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 9.28 million shares valued at $9.46 million to account for 4.526 of the shares outstanding. The other top investors are ALERCE INVESTMENT MANAGEMENT, L.P. which holds 5.75 million shares representing 2.8045 and valued at over $5.86 million, while GEODE CAPITAL MANAGEMENT, LLC holds 2.2133 of the shares totaling 4.54 million with a market value of $4.63 million.
Akebia Therapeutics Inc. (AKBA) Insider Activity
The most recent transaction is an insider sale by Hadas Nicole R., the company’s SVP, Chief Legal Officer. SEC filings show that Hadas Nicole R. sold 12,016 shares of the company’s common stock on May 13 ’24 at a price of $1.26 per share for a total of $15140.0. Following the sale, the insider now owns 0.65 million shares.
Akebia Therapeutics Inc. disclosed in a document filed with the SEC on May 13 ’24 that Dahan Michel (SVP, Chief Operating Officer) sold a total of 34,840 shares of the company’s common stock. The trade occurred on May 13 ’24 and was made at $1.26 per share for $43898.0. Following the transaction, the insider now directly holds 0.67 million shares of the AKBA stock.
Still, SEC filings show that on Feb 29 ’24, Dahan Michel (SVP, Chief Operating Officer) disposed off 8,661 shares at an average price of $1.58 for $13684.0. The insider now directly holds 706,932 shares of Akebia Therapeutics Inc. (AKBA).
